Reteplase (rt-PA) is the third generation of thrombolytic agents for treating acute myocardial infarction and structurally a single-chain non-glycosylated deletion mutant of wild-type tissue plasminogen activator (t-PA), consisting of only the Kringle II and protease domain [14,15]. Here, PLAT is linked to myocardial infarction.